Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome

Andrea M. Haqq, Diane Stadler, Russell H. Jackson, Ronald (Ron) Rosenfeld, Jonathan Purnell, Stephen Lafranchi

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

The objective of this study was to investigate the effects of GH administration on pulmonary function, sleep, behavior, cognition, linear growth velocity, body composition, and resting energy expenditure (REE) in children with Prader-Willi syndrome. The study used a 12-month, balanced, randomized, double-blind, placebo-controlled, cross-over experimental design. Twelve subjects were randomized to GH (0.043 mg/kg·d) or placebo intervention for 6 months and then crossed over to the alternate intervention for 6 months. Differences in outcome variables were determined by paired t tests. Peak flow rate, percentage vital capacity, and forced expiratory flow rate improved and number of hypopnea and apnea events and duration of apnea events trended toward improvement after GH intervention. The only difference in cognition or behavior was an increase in hyperactivity scale on the Behavior Assessment System for Children after GH intervention. Linear growth velocity, REE, and lean mass were higher (67%, 19%, and 7.6%, respectively), and fat mass and percentage body fat were lower (10.3% and 8.1%, respectively) after GH intervention. GH administration did not change mean fasting ghrelin concentration. GH intervention improved body composition and REE and may contribute to better sleep quality and pulmonary function. GH administration did not impact fasting ghrelin concentration.

Original languageEnglish (US)
Pages (from-to)2206-2212
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume88
Issue number5
DOIs
StatePublished - May 1 2003

Fingerprint

Prader-Willi Syndrome
Body Composition
Cognition
Energy Metabolism
Growth Hormone
Sleep
Ghrelin
Apnea
Lung
Fasting
Forced Expiratory Flow Rates
Growth
Chemical analysis
Fats
Placebos
Flow rate
Vital Capacity
Design of experiments
Cross-Over Studies
Adipose Tissue

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. / Haqq, Andrea M.; Stadler, Diane; Jackson, Russell H.; Rosenfeld, Ronald (Ron); Purnell, Jonathan; Lafranchi, Stephen.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 88, No. 5, 01.05.2003, p. 2206-2212.

Research output: Contribution to journalArticle

@article{f1d973eef72043a981c67a84b21c7072,
title = "Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome",
abstract = "The objective of this study was to investigate the effects of GH administration on pulmonary function, sleep, behavior, cognition, linear growth velocity, body composition, and resting energy expenditure (REE) in children with Prader-Willi syndrome. The study used a 12-month, balanced, randomized, double-blind, placebo-controlled, cross-over experimental design. Twelve subjects were randomized to GH (0.043 mg/kg·d) or placebo intervention for 6 months and then crossed over to the alternate intervention for 6 months. Differences in outcome variables were determined by paired t tests. Peak flow rate, percentage vital capacity, and forced expiratory flow rate improved and number of hypopnea and apnea events and duration of apnea events trended toward improvement after GH intervention. The only difference in cognition or behavior was an increase in hyperactivity scale on the Behavior Assessment System for Children after GH intervention. Linear growth velocity, REE, and lean mass were higher (67{\%}, 19{\%}, and 7.6{\%}, respectively), and fat mass and percentage body fat were lower (10.3{\%} and 8.1{\%}, respectively) after GH intervention. GH administration did not change mean fasting ghrelin concentration. GH intervention improved body composition and REE and may contribute to better sleep quality and pulmonary function. GH administration did not impact fasting ghrelin concentration.",
author = "Haqq, {Andrea M.} and Diane Stadler and Jackson, {Russell H.} and Rosenfeld, {Ronald (Ron)} and Jonathan Purnell and Stephen Lafranchi",
year = "2003",
month = "5",
day = "1",
doi = "10.1210/jc.2002-021536",
language = "English (US)",
volume = "88",
pages = "2206--2212",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome

AU - Haqq, Andrea M.

AU - Stadler, Diane

AU - Jackson, Russell H.

AU - Rosenfeld, Ronald (Ron)

AU - Purnell, Jonathan

AU - Lafranchi, Stephen

PY - 2003/5/1

Y1 - 2003/5/1

N2 - The objective of this study was to investigate the effects of GH administration on pulmonary function, sleep, behavior, cognition, linear growth velocity, body composition, and resting energy expenditure (REE) in children with Prader-Willi syndrome. The study used a 12-month, balanced, randomized, double-blind, placebo-controlled, cross-over experimental design. Twelve subjects were randomized to GH (0.043 mg/kg·d) or placebo intervention for 6 months and then crossed over to the alternate intervention for 6 months. Differences in outcome variables were determined by paired t tests. Peak flow rate, percentage vital capacity, and forced expiratory flow rate improved and number of hypopnea and apnea events and duration of apnea events trended toward improvement after GH intervention. The only difference in cognition or behavior was an increase in hyperactivity scale on the Behavior Assessment System for Children after GH intervention. Linear growth velocity, REE, and lean mass were higher (67%, 19%, and 7.6%, respectively), and fat mass and percentage body fat were lower (10.3% and 8.1%, respectively) after GH intervention. GH administration did not change mean fasting ghrelin concentration. GH intervention improved body composition and REE and may contribute to better sleep quality and pulmonary function. GH administration did not impact fasting ghrelin concentration.

AB - The objective of this study was to investigate the effects of GH administration on pulmonary function, sleep, behavior, cognition, linear growth velocity, body composition, and resting energy expenditure (REE) in children with Prader-Willi syndrome. The study used a 12-month, balanced, randomized, double-blind, placebo-controlled, cross-over experimental design. Twelve subjects were randomized to GH (0.043 mg/kg·d) or placebo intervention for 6 months and then crossed over to the alternate intervention for 6 months. Differences in outcome variables were determined by paired t tests. Peak flow rate, percentage vital capacity, and forced expiratory flow rate improved and number of hypopnea and apnea events and duration of apnea events trended toward improvement after GH intervention. The only difference in cognition or behavior was an increase in hyperactivity scale on the Behavior Assessment System for Children after GH intervention. Linear growth velocity, REE, and lean mass were higher (67%, 19%, and 7.6%, respectively), and fat mass and percentage body fat were lower (10.3% and 8.1%, respectively) after GH intervention. GH administration did not change mean fasting ghrelin concentration. GH intervention improved body composition and REE and may contribute to better sleep quality and pulmonary function. GH administration did not impact fasting ghrelin concentration.

UR - http://www.scopus.com/inward/record.url?scp=0038030751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038030751&partnerID=8YFLogxK

U2 - 10.1210/jc.2002-021536

DO - 10.1210/jc.2002-021536

M3 - Article

C2 - 12727976

AN - SCOPUS:0038030751

VL - 88

SP - 2206

EP - 2212

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -